Kevin Taylor - Chief Executive Officer

  • Seasoned Pharma and Biotech corporate development executive with over 25 years experience in drug development, fundraising, licensing and transaction
  • Previous company officer at Altor Bioscience, Nuron Biotech, Cangene Corporation, Adolor Corporation, Codexis Inc., Elan Corporation and  AstraZeneca
Aless.png

Alessandro Fatatis, MD, PhD - Chief Scientific Officer

  • Professor of Pharmacology and Pathology at Drexel University College of Medicine
  • Co-Leader, Program in Prostate Cancer, SKCC at Thomas Jefferson University
  • Experimental Oncologist with 15 years experience in prostate and breast cancers

Shawn Bridy, MA, MBA - Chief Financial Officer

  • Venture Partner, Militia Hill Venture
  • Over 20 years of experience in biotech and pharmaceutical transactions and finance. Senior positions at Immunome, Elan, GSK, and BTG plc
     

 

JS.png


Joseph Salvino, PhD - Head of Drug Discovery

  • Professor of Pharmacology and Physiology at Drexel University College of Medicine
  • Seasoned Medicinal Chemist – 20 years of experience in drug discovery and lead optimization in Pharma and Biotech 
 
 

Olimpia Meucci, MD, PhD - Head of Pre-Clinical Research

  • Professor and Chair, Department of Pharmacology and Physiology at Drexel University College of Medicine
  • Deputy Director of the Clinical and Translational Research Institute at Drexel University College of Medicine
  • Molecular Pharmacologist – 20 years of experience in chemokine signaling
 
 

Richard Labaudiniere, PhD - Chairman

  • Drug discovery and development consultant
  • Former CEO of FoldRx Pharmaceuticals when purchased by Pfizer in 2010
  • 30 years of experience in Pharma and Biotech industry